We are comparing Apollo Endosurgery Inc. (NASDAQ:APEN) and MiMedx Group Inc. (OTCMKTS:MDXG) on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. They both are Medical Appliances & Equipment companies, competing one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Apollo Endosurgery Inc.||61.81M||1.42||34.75M||-1.87||0.00|
|MiMedx Group Inc.||303.47M||1.25||35.33M||0.31||9.87|
Table 1 shows the top-line revenue, earnings per share and valuation for Apollo Endosurgery Inc. and MiMedx Group Inc.
Table 2 represents Apollo Endosurgery Inc. (NASDAQ:APEN) and MiMedx Group Inc. (OTCMKTS:MDXG)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Apollo Endosurgery Inc.||-56.22%||-71.7%||-33.1%|
|MiMedx Group Inc.||11.64%||0%||0%|
Insider & Institutional Ownership
Institutional investors held 64.4% of Apollo Endosurgery Inc. shares and 70.08% of MiMedx Group Inc. shares. About 10% of Apollo Endosurgery Inc.’s share are held by insiders. Comparatively, insiders own roughly 7.5% of MiMedx Group Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Apollo Endosurgery Inc.||-3.33%||0.29%||-14.91%||-52.97%||-48.75%||0.87%|
|MiMedx Group Inc.||-3.46%||16.51%||1.66%||-34.12%||-57.77%||71.51%|
For the past year Apollo Endosurgery Inc. was less bullish than MiMedx Group Inc.
MiMedx Group Inc. beats Apollo Endosurgery Inc. on 9 of the 11 factors.
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The companyÂ’s proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.